Announced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for ...
16h
Enerflex Ltd. Announces Third Quarter 2025 Financial and Operational Results and Increased Dividend
Enerflex Ltd. (TSX: EFX) (NYSE: EFXT) (“Enerflex” or the “Company”) today reported its financial and operational results for the three and nine months ended September 30, 2025. All amounts presented ...
LithiX™ HC-IVL is a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback